Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts
Dimitra Kerdidani, Emmanouil Aerakis, Kleio‐Maria Verrou, Ilias Angelidis, Katerina Douka, Maria-Anna Maniou, Petros Stamoulis, Katerina Goudevenou, Alejandro Prados, Christos Tzaferis, Vasileios Ntafis, Ioannis Vamvakaris, Evangelos Kaniaris, Κonstantinos Vachlas, Evangelos Sepsas, Anastasios Koutsopoulos, Κonstantinos Potaris, Maria Tsoumakidou
Abstract
A key unknown of the functional space in tumor immunity is whether CD4 T cells depend on intratumoral MHCII cancer antigen recognition. MHCII-expressing, antigen-presenting cancer-associated fibroblasts (apCAFs) have been found in breast and pancreatic tumors and are considered to be immunosuppressive. This analysis shows that antigen-presenting fibroblasts are frequent in human lung non-small cell carcinomas, where they seem to actively promote rather than suppress MHCII immunity. Lung apCAFs directly activated the TCRs of effector CD4 T cells and at the same time produced C1q, which acted on T cell C1qbp to rescue them from apoptosis. Fibroblast-specific MHCII or C1q deletion impaired CD4 T cell immunity and accelerated tumor growth, while inducing C1qbp in adoptively transferred CD4 T cells expanded their numbers and reduced tumors. Collectively, we have characterized in the lungs a subset of antigen-presenting fibroblasts with tumor-suppressive properties and propose that cancer immunotherapies might be strongly dependent on in situ MHCII antigen presentation.